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Acid specific dark quencher 
QC1 pHLIP for multi-spectral 
optoacoustic diagnoses of breast 
cancer
Sheryl Roberts  1, Arianna Strome1, Crystal Choi1, Chrysafis Andreou  1, Susanne Kossatz 
 1, Christian Brand  1, Travis Williams  1, Michelle Bradbury  1,2, Moritz F. Kircher  1,2,3,4,5, 
Yana K. Reshetnyak6, Jan Grimm  1,4,7,8, Jason S. Lewis  1,4,8,9,10 & Thomas Reiner  1,4,11
Breast cancer is the most common type of malignant growth in women. Early detection of breast 
cancer, as well as the identification of possible metastatic spread poses a significant challenge because 
of the structural and genetic heterogeneity that occurs during the progression of the disease. Currently, 
mammographies, biopsies and MRI scans are the standard of care techniques used for breast cancer 
diagnosis, all of which have their individual shortfalls, especially when it comes to discriminating 
tumors and benign growths. With this in mind, we have developed a non-invasive optoacoustic imaging 
strategy that targets the acidic environment of breast cancer. A pH low insertion peptide (pHLIP) was 
conjugated to the dark quencher QC1, yielding a non-fluorescent sonophore with high extinction 
coefficient in the near infrared that increases signal as a function of increasing amounts of membrane 
insertion. In an orthotopic murine breast cancer model, pHLIP-targeted optoacoustic imaging allowed 
us to differentiate between healthy and breast cancer tissues with high signal/noise ratios. In vivo, the 
sonophore QC1-pHLIP could detect malignancies at higher contrast than its fluorescent analog ICG-
pHLIP, which was developed for fluorescence-guided surgical applications. PHLIP-type optoacoustic 
imaging agents in clinical settings are attractive due to their ability to target breast cancer and a wide 
variety of other malignant growths for diagnostic purposes. Intuitively, these agents could also be used 
for visualization during surgery.
Malignant growths originate from alterations in the genome, including changes in epigenetic regulation, point 
mutations, gene deletions, duplications and chromosomal rearrangements1. While there have been significant 
developments in diagnosis and treatment of malignant tumors, treatment of many cancers remains a challenge 
due to difficulties in diagnosing and identifying them without advanced, and infrastructure-heavy equipment. 
This is particularly relevant in breast cancer, the most common diagnosed cancer in women, affecting almost 
270,000 new individuals yearly in the US alone2–4. For breast cancer, early detection of primary tumors signifi-
cantly improves overall survival2. The survival differences are most pronounced between breast cancer patients 
that were diagnosed with either local versus non-local tumors. Women with localized tumors, which represent 
1Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 
10065, USA. 2Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, New 
York, 10065, USA. 3Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer 
Center, New York, NY, 10065, USA. 4Department of Radiology, Weill Cornell Medical College, 1300 York Avenue, 
New York, New York, 10065, USA. 5Department of Imaging, Dana-Farber Cancer Institute/Harvard Medical School, 
Boston, MA 02215, USA. 6Department of Physics, University of Rhode Island, 2 Lippitt Rd, Kingston, RI, 02881, 
USA. 7Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, 
USA. 8Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA. 9Molecular Pharmacology 
Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10Radiochemistry and Molecular Imaging 
Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 11Chemical Biology Program, Memorial 
Sloan Kettering Cancer Center, New York City, NY, 10065, United States. Correspondence and requests for materials 
should be addressed to T.R. (email: reinert@mskcc.org)
Received: 18 January 2019
Accepted: 20 May 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:8550  | https://doi.org/10.1038/s41598-019-44873-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
60% of the total breast cancer population, have a >99% 5-year survival rate. The survival rate drops to 70–85% for 
regional and to 25% for distant metastases. Intuitively, diagnosing breast cancer early represents major benefits in 
terms of increased survival and also decreased number of treatments. For increasing the number of patients who 
are diagnosed when their disease is still local, non-invasive and early screening technologies are critical.
Regular systematic screening for breast cancer is therefore key in increasing the overall survival rate5,6. Despite 
improvements in mammography techniques, breast magnetic resonance imaging (MRI) is complementary for 
screening asymptomatic women at increased risk of breast cancer7. This is partly due to the limited sensitivity 
of mammograms, which declines markedly with increasing breast density and leads to false-negative results5,8,9. 
Women with high breast densities are often screened with ultrasound (US)10, but detected abnormalities are often 
found to be not cancer11,12. The combination of these screening tests (mammography/ultrasound and breast MRI) 
is effective, but it is avoided in practice for an average risk patient due to higher cost13,14. Optoacoustic imaging 
on the other hand has evolved into a clinically translatable platform which can provide limited functional and 
molecular information15. The impact of optoacoustic imaging has been shown through a number of clinical stud-
ies for various breast screening of patients16–20. It has the primary advantage of imaging at depths of up to 7 cm 
with submillimeter resolution, high contrast to noise ratio, real time acquisition, portability and does not require 
ionizing radiation21,22,23. In the near future, optoacoustic imaging systems could be the cost-effective alternative 
for first point of care testing.
So far, optoacoustic imaging often relied on contrast free methods, but to enable a molecularly specific read-
out, sonophores could be necessary24. In breast imaging, tumor heterogeneity limits the general use of cell surface 
biomarkers for breast cancer imaging25,26. On the other hand, one general finding which is largely independ-
ent from an individual tumor cell’s expression profile is that the pH at the surface of cancer cells is lower than 
bulk extracellular pH27. The surface acidity of cancer cells is a general physical characteristic that is independent 
of tumor perfusion and found across an entire tumor26,28–30. Therefore, a low pH is a key characteristic in an 
alternative targeted imaging approach. We hypothesized that a low pH optoacoustic tracer would enable us to 
non-invasively image breast cancers.
The water soluble pH low insertion peptides (pHLIPs) are a class of membrane-binding peptides which target 
acidity at the surface of cancer cells31. Their mechanism of action is based on the protonation of aspartic and glu-
tamic acid residues, which induces a conformational change of pHLIP’s secondary structure and allows the pep-
tide to insert itself into cell membranes. Indocyanine green (ICG) is a well-established fluorescent dye in scientific 
literature and its use in humans is known for a variety of fluorescence and optoacoustic imaging applications32–38. 
A pHLIP peptide conjugated with indocyanine green (ICG) has recently been reported to differentiate normal 
from neoplastic tissue in various animal tumor models39–42. To date, however, only one study was carried out 
using a fluorescent pHLIP for optoacoustic imaging43. One of the most striking advantages of ICG-pHLIP is that 
upon binding to cells, fluorescence is enhanced by 20–25 times, which increases the tumor to background ratio35. 
While, intuitively, this enhancement represents a significant advantage for fluorescence imaging, it is a disadvan-
tage for optoacoustic imaging, a technology that is based on the generation of acoustic signals which rely on the 
energy transfer to heat (non-radiative decay). An imaging agent which does not disseminate its absorbed energy 
through photons could therefore be more advantageous to consider for optoacoustic applications.
With this in mind, we became interested in exploring whether dark quenchers could achieve stronger 
optoacoustic signals than ICG44–46. Dark quenchers have gained some attention and holds promise to gener-
ate higher optoacoustic signals than their more commonly used fluorescent counterparts since they are strong 
absorbers and undergo non-radiative decay44,45,47,48. The dark quencher IRDye QC1 is structurally similar to ICG 
(Fig. S1a), but features an aromatized ring system at its center, increasing the rigidity of the structure by reducing 
internal energy conversion and the tendency for self-aggregation49. IRDye QC1 is therefore structurally more 
robust than ICG.
Using the dark quencher conjugated to pHLIP, QC1-pHLIP, we aim to explore two clinically relevant ques-
tions: (i) Does multi-spectral optoacoustic tomography (MSOT) with QC1-pHLIP allow non-invasive deline-
ation of breast cancer in a murine orthotopic breast cancer model? (ii) How does the sonophore QC1-pHLIP 
compare as an optoacoustic tool to fluorescent ICG-pHLIP? We believe that molecularly targeted sonophores can 
overcome several hurdles currently hampering the development and broad clinical use of the MSOT. We believe 
that optimizing and validating QC1 pHLIP for cancer detection is of high value for detecting both localized and 
non-localized breast tumors. Such an optoacoustic imaging strategy could reduce the frequencies of biopsies, 
provide accurate monitoring of breast tumors and increase the precision of surgical interventions.
Results
Optoacoustic characterization of ICG-pHLIP and QC1-pHLIP. Variant3 pH low insertion peptide 
(pHLIP) is a synthetic peptide derived from the C-helix of bacteriorhodopsin which contains 27 amino acids 
with the following sequence: (D-Ala)-(D-Cys)-(D-Asp)-(D-Asp)-(D-Gln)-(D-Asn)-(D-Pro)-(D-Trp)-(D-Arg)-
(D-Ala)-(D-Tyr)-(D-Leu)(D-Asp)-(D-Leu)-(D-Leu)-(D-Phe)-(D-Pro)-(D-Thr)-(D-Asp)-(D-Thr)-(D-Leu)-(D-
Leu)-(D-Leu)-(D-Asp)-(D-Leu)-(D-Leu)-(D-Trp). To provide the first optoacoustic dark quencher pHLIP, the 
focus was on obtaining QC1-pHLIP as an acid specific probe, capable of sensing and targeting acidity at the 
surface of cancer cells in tumors. The scheme of QC1-pHLIP and its mode of action is shown in Fig. 1. To obtain 
the dark quencher, IRDye QC1 maleimide was cross-linked to a pH sensitive var3 pHLIP at the second amino 
acid position which is a cysteine (-SH) to obtain QC1-pHLIP (70%). Both IRDye QC1 (Fig. S1a (left)) and ICG 
(Fig. S1a (right)) belong to the cyanine dye family. The IRDye QC1 is a subclass of heptamethine type, containing 
a heterocyclic ring in the center giving rise to a more photostable dye than its parent cyanine family dyes. Full 
chemical characterization of QC1-pHLIP is shown in Fig. S1. At the same HPLC buffer conditions, the retention 
time, tR of var3 pHLIP was found at 17.9 min (95.3% AcN), whereas QC1-pHLIP was found at 17.0 min (99.2% 
AcN). The retention time of ICG-pHLIP was 28.0 min (97.7% AcN). At the same concentration, the appearance of 
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QC1-pHLIP is dark teal, whereas ICG-pHLIP appears green. The extinction coefficient of QC1-pHLIP at 810 nm 
is 41,000 cm−1 M−1 and it is similar to the extinction coefficient of ICG-pHLIP at 810 nm which is 42 000 cm−1 
M−1, shown in Fig. S2. Optoacoustic characterizations were assessed using a custom-made optoacoustic flow 
phantom device that was built to fit into the commercially available MSOT phantom holder (Fig. 2a). Described 
in the methods section in detail, a phantom was prepared to mimic the light absorption, scattering and depth 
attenuation of soft tissue. Briefly, the agarose phantom contained Direct Red 81 to mimic the optical absorp-
tion and lipids to mimic the scattering of light. Increasing the amount of agarose from 1.5% to 5% permitted 
a more robust imaging flow set up. Using this setup, the optoacoustic signals of ICG-pHLIP and QC1-pHLIP 
were tested at various concentrations of 2 µM, 5 µM, 10 µM, 15 µM and 20 µM (all groups n = 3) and were found 
to be comparable to each other in the absence of cells (Fig. 2b). The corresponding optoacoustic spectra (a.u.) of 
ICG-pHLIP (Fig. 2c, left) and QC1-pHLIP (Fig. 2c, right) are shown and directly compared with the shape of its 
UV/Vis absorption spectra (Fig. 2d). ICG-pHLIP has a distinct optoacoustic shoulder band at 710 nm, whereas 
QC1-pHLIP notably only has one broad peak (Fig. 2e). A classical least square (CLS) model was used for spectral 
unmixing of signals, shown in Fig. 2f, using the optoacoustic spectra found in Fig. 2e.
Concentration dependent increase of ICG-pHLIP loses optoacoustic signal in vitro. Fluorescent 
dyes such as ICG are known to quench at higher concentrations50. While evaluating the acoustic nature of the 
pHLIP imaging agents in vitro, the fluorescent behavior of ICG-pHLIP was also assessed. ICG-pHLIP was incu-
bated with increasing numbers of cells of the murine breast cancer cell line 4T1 (0.1 × 106, 0.5 × 106, 1 × 106 and 
5 × 106 cells) in phosphate buffered saline (PBS) media containing 10% glucose for 7 min at 37 °C). Increasing 
the concentrations of 4T1 cells while keeping the pHLIPs concentration constant at 5 µM, yielded dramatically 
increased fluorescence (Fig. 3a,b). The biggest signal change occurs when changing from cell-free media to 
0.1 × 106 cells (16-fold increase). Fluorescence signal difference starts to plateau after that (Fig. S6) with only 
30%–70% signal enhancement going from 0.1 × 106 to 5 × 106 cells. As expected and shown in Fig. 3a, no fluores-
cence was observed for QC1-pHLIP in vitro (Fig. S7). For ICG-pHLIP, binding to cells causes a dramatic increase 
in fluorescence (Fig. 3a (top) and 3b), and it was therefore critical to assess the behavior of both the fluorescent 
ICG-pHLIP and dark quencher QC1-pHLIP in an optoacoustic in vitro setting. Using the same experimental 
conditions carried out in the fluorescence imaging setting, the optoacoustic flow phantom device was used. 
Plotting the optoacoustic imaging intensities (a.u.) at various wavelengths (680–900 nm, n = 3) and spectrally 
unmixed CLS score for ICG-pHLIP (Fig. 3c,e), showed that there was a trend that the signal was decreasing with 
increasing concentrations of 4T1 cells (optoacoustic intensities p > 0.05, CLS score p > 0.05). In comparison, the 
optoacoustic signal of QC1-pHLIP was found to increase with increasing concentrations of 4T1 cells (Fig. 3d,f, 
n = 3) and the statistical significance was found between cell-free media and 0.1 × 106 cells (****p = 0.0001) and 
1 × 106 cells (optoacoustic intensities ****p < 0.0001, CLS score ***p = 0.0002).
Figure 1. QC1 pH low insertion peptide (pHLIP) targets acidity at the surface of cancer cells and allows multi-
spectral optoacoustic imaging. (a) Schematic of var3 pHLIP at three distinct conditions (left to right). pHLIP 
is unstructured in aqueous solution at physiological pH (state I) and it binds to the surface of a cell membrane 
(state II). At acidic pH, pHLIP changes into an α-helix conformation and inserts in between the membrane 
with the C-terminal found within the intracellular space and the N-terminal extruding towards the extracellular 
space. (b) The structure of IRDye QC1 conjugated to the N-terminal of var3 pHLIP. (c) High performance 
liquid chromatogram (HPLC) at 280 nm of QC1 var3 pHLIP.
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Figure 2. Fluorescent ICG-pHLIP and dark quencher QC1-pHLIP have comparable optoacoustic intensities at 
the same concentration in tissue mimicking phantoms. (a) An optoacoustic imaging flow setup using soft-tissue 
mimicking phantoms (right) was used with the MSOT whole animal imaging setup (left). (b) Optoacoustic 
characterizations of ICG-pHLIP and QC1-pHLIP at varying concentrations (2 µM, 5 µM, 10 µM, 15 µM and 
20 µM) in DMSO. Optoacoustic intensities at 680 nm were overlaid with the spectrally unmixed signals of 
ICG-pHLIP (green) or QC1-pHLIP (cyan). (c) The optoacoustic spectra (a.u.) of ICG-pHLIP (left) and QC1-
pHLIP (right). (d) The UV/Vis absorbance spectra of ICG-pHLIP and QC1-pHLIP at 5 µM deviates from the 
optoacoustic spectra of ICG-pHLIP and QC1-pHLIP (e, middle) taken at the same concentrations (15 µM). (f, 
right) Classical least square (CLS) fit at varying concentrations of the two pHLIPs after multi-spectral unmixing 
with the spectra references shown in (e, middle).
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Dark Quencher QC1-pHLIP outperforms fluorescent ICG-pHLIP in ex vivo optoacoustic imaging. 
For comparing the sonophore QC1-pHLIP to its fluorescent counterpart ICG-pHLIP, an orthotopic murine 
breast cancer model was set up. Imaging for both ICG-pHLIP and QC1-pHLIP (120 µM, 200 µL) was performed 
24 h post i.v. injection. The mice were sacrificed and transcardial perfusion was carried out with saline before 
major organs of interest (tumor, muscle, spleen kidney and liver) were resected. The high optical density of blood 
represents a major component of the endogenous optoacoustic signal and thus, excised organs were imaged with 
and without prior perfusion (Fig. S8). Optoacoustic imaging of ex vivo organs (ICG-pHLIP, QC1-pHLIP and 
non-injected controls) were lined up on top of a clear plastic membrane coated with colorless ultrasound gel 
(Fig. 4a). Optoacoustic signal quantification of tumor (Fig. 4b) and muscle (Fig. 4c) before and 24 h post injection 
Figure 3. In vitro fluorescence and opposing optoacoustic binding signal of fluorescent ICG-pHLIP (green) 
and dark quencher QC1-pHLIP (cyan) to murine breast cancer cell line 4T1. (a) ICG-pHLIP (5 µM) is a 
turn-on fluorescent probe with zero fluorescence in cell-free media. Fluorescence was immediately observed 
when pHLIP inserts into the lipid bilayer of plasma membrane at low pH found at the surface of 4T1 cells 
(n = 9, scale bar from 0 to 65535). Optoacoustic signal is inversely proportional to the number of cells incubated 
with ICG-pHLIP, whereas it increases proportionally for cells incubated with QC1 pHIP. (b) Quantification of 
ICG-pHLIP fluorescence signal increases as the number of cells increases. QC1-pHLIP has negligible signal. 
(c) For ICG-pHLIP, overall optoacoustic instensities (a.u) decreases as the number of cells incubated with 
ICG-pHLIP (5 µM) is increased. (d) For QC1-pHLIP, optoacoustic signal increases as the number of cells 
incubated with QC1-pHLIP (5 µM) is increased. (e) Spectrally unmixed signal shows ICG-pHLIP is a signal-
off optoacoustic agent and complicates quantification, whereas (f), QC1-pHLIP is a signal-on probe, provides 
clear quantifiable signal with high significance. Ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 (unpaired t-test).
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of either QC1-pHLIP (left) and ICG pHLIP (right) were obtained. Ex vivo tumors of QC1-pHLIP injected mice 
showed higher optoacoustic signals, with QC1-pHLIP showing about 33-fold (mean 32.59 ± 11.74, n = 4) signal 
enhancement between the injected and non-injected group tumors (**p = 0.003), shown in Fig. 4d. In compari-
son, ICG-pHLIP injected mice yielded signal enhancement at roughly 2-fold (2.25 ± 1.46, n = 4) and it was found 
to be not statistically significant (p > 0.05). Muscle tissue was harvested as a control from the same respective 
mice with ICG-pHLIP (1.25 ± 0.01, n = 4) and QC1-pHLIP 1.67 (1.67 ± 0.10, n = 4). Both of the tracers also 
accumulated in the spleen, kidney and liver (Figs S9–S10), consistent with earlier reports using labeled pHLIP 
constructs40,51–53.
QC1-pHLIP yields higher optoacoustic signals in vivo. Although ICG-pHLIP and QC1-pHLIP are 
both highly tumor-specific tracers, the differences in ex vivo studies were notable, with QC1-pHLIP clearly 
outperforming ICG-pHLIP in optoacoustic sensitivity (Fig. 4). Next, the non-invasive MSOT system was used 
to compare the degree of signal (sensitivity) at the tumor site between ICG-pHLIP and QC1-pHLIP in vivo. 
Representative optoacoustic images of ICG-pHLIP and QC1-pHLIP shown in Fig. 5a,b respectively, showing 
tumor uptake for both imaging agents. The corresponding tumor insets showing 3 mm of cross-sections shows 
the accumulation and distribution of the pHLIP agents through the tumor site. Overall optoacoustic intensi-
ties, shown in Fig. 5c, for ICG-pHLIP (****p < 0.0001) and QC1-pHLIP (****p < 0.0001) show statistical sig-
nificant differences between the pre-injected and injected groups at all wavelengths from 680–900 nm. In line 
with the optoacoustic signal quantification data presented in Fig. 5d, both ICG-pHLIP (**p = 0.0211) and 
QC1-pHLIP (**p = 0.0013) corroborated statistically significant differences in tumor signal before and after 
Figure 4. Dark quencher QC1-pHLIP outperforms fluorescent ICG-pHLIP in ex vivo optoacoustic imaging 
24 h post intravenous injection in an orthotopic murine breast cancer model. (a) Optoacoustic images of 
tumors (top) and muscles (bottom) harvested from mice, non injected or injected with either QC1-pHLIP 
(cyan, left) or ICG-pHLIP (green, right) 24 h post injection. (b) Signal from QC1-pHLIP and ICG-pHLIP 
shows accumulation of the agents in the tumor. (c) Muscle tissue was used as control and showed no signal 
difference between non-injected and injected mice with either agent. (d) At the same injected dose of 120 µM, 
the accumulation of QC1-pHLIP in tumors is more visible than ICG-pHLIP (24 h post intravenous injection), 
yielding a 33-fold increase in optoacoustic signal as compared to 2-fold increase observed in ICG-pHLIP 
(each group, n = 4 non injected, n = 4 injected). Ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 (unpaired t-test).
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injection (Fig. 5c,d). The background (non tumor regions) produces insignificant optoacoustic signal compared 
to injected tumor area and it is comparable to the optoacoustic background of the pre injected tumor (Fig. S15). 
The deoxyhemoglobin (Hb) status of the tumor is useful to locate the tumor margins (Fig. S16) and aid accu-
rate determination for the regions of interest (ROI). QC1-pHLIP yielded a 96% signal enhancement after 24 h 
post injection, whereas ICG-pHLIP yielded 35% signal enhancement. The fluorescence and histology (H&E) 
sections showed no signs of toxicity at 120 µM (200 µL) injected dose and the pHLIP-type imaging agent tar-
gets the viable tumor tissue of the mouse breast cancer model via membrane insertion (Fig. 5e). The ideal in 
vivo optoacoustic imaging time points for the highest signal/noise ratio was determined at 24 h post injection 
of QC1 pHLIP (Figs S11 and S12). Further validation were carried out with in vivo fluorescence imaging of 
ICG-pHLIP (Fig. S13). Representative fluorescent images of ICG-pHLIP, QC1-pHLIP and non-injected mice are 
shown in Fig. S13a at 24 h post injection. It confirms the accumulation of ICG-pHLIP in the tumor and similar 
Figure 5. MSOT Imaging performance of dark quencher QC1-pHLIP in a murine breast cancer model 
outperforms fluorescent ICG-pHLIP. Axial tomographic slices through the tumors before and 24 h after tail 
vein injection demonstrate specific ICG-pHLIP (a) and QC1-pHLIP (b) signals in an orthotopic murine breast 
cancer model. Tomographic sections of tumors from three different planes (xy, xz and yz) demonstrate targeted 
distribution of both pHLIPs through the tumor. Scale bar (white) is 2.5 mm, optoacoustic intensity (a.u.) scale 
is from 4.3 × 101 to 2.8 × 102 (grey scale), CLS score scale is from 7.8 × 101 to 2.1 × 102 (green/cyan). (c) Overall 
optoacoustic intensities of pre-injected (grey, n = 4) and post injected mice (n = 4) of either ICG-pHLIP (left, 
green) or QC1-pHLIP (right, cyan) at varying wavelengths (680–900 nm). (d) Representative fluorescent 
image of excised tumors from ICG-pHLIP injected mice and their corresponding H&E staining. Fluorescent 
microscopy of the tumors shows membrane insertion and distribution within tumor tissue. No fluorescence 
was observed in non-injected mice. (e) The accumulation of QC1-pHLIP in the tumor yielded 96% signal 
enhancement as compared to 35% for ICG-pHLIP.
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pharmacokinetic profile was found for QC1-pHLIP. The accumulation of ICG-pHLIP and QC1-pHLIP starts to 
plateau between 4 h and 24 h (Figs S11 and S13b).
Discussion
Although QC1-pHLIP and ICG-pHLIP have similar optoacoustic intensities in the absence of biological materials 
(Fig. 2), the differences between the two pHLIP constructs became apparent in vitro and in vivo (Fig. 3 and Fig. 5). 
In an orthotopic murine breast cancer 4T1 model that mimics the physiopathology of breast cancer, we tested (i) 
a pHLIP sonophore and (ii) a pHLIP fluorophore. In 4T1 bearing mice, both agents targeted the acidic environ-
ment of breast cancer ex vivo and in vivo (Figs 4 and 5). The direct comparison of QC1-pHLIP to ICG-pHLIP 
demonstrated that the dark quencher sonophore yielded higher signal/noise ratios for differentiating malignant 
from healthy tissues in optoacoustic imaging as compared to the more commonly used fluorophore.
Despite the acidic nature of cancers being known for over 100 years54, only in recent decades that acidity has 
been identified and exploited as a biomarker. Var3 pHLIP was chosen based on its high potential for clinical 
translation39. Not only is var3 pHLIP an effective pH specific probe, differentiating between metastatic lesions and 
measuring tumor aggressiveness35, it has been shown to target several malignant growths that are otherwise hard 
to diagnose, including bladder cancer35, triple negative breast cancers30, head and neck cancers55 and pancreatic 
cancers42,43. Its unique capabilities make it a potential candidate for universal targeting of cancer, and some pHLIP 
agents will be entering the clinical realm in 201953,56.
Using an imaging agent that does not emit energy in the form of photons (as fluorophores do) could provide 
higher signal intensities for optoacoustic imaging applications. QC1, a dark quencher, dissipates its absorbed 
energy mostly in the form of non-radiative decay. A large portion of energy is emitted via internal conversions, 
which are non-radiative transitions in the form of heat. In addition, QC1-pHLIP targets a low pH environment, 
a universal biomarker for cancers and offers several advantages for in vivo delivery as compared to other contrast 
agents which have been reported for optoacoustic imaging57. Most contrast agents target receptors at the surface 
of cancer cells, a strategy with several potential drawbacks, including limited agent delivery to the site of the target 
and an insufficient amount of receptors at the surface to create high signals. Recent fluorescence-based studies of 
pHLIP show that the substance-class is non-toxic and highly specific to the acidic environment. With this in mind, 
QC1-pHLIP could be used in targeting a wide variety of cancers in pre-operative imaging where it is essential to 
determine resectability, particularly with borderline tumors. Due to their size, small peptide based sonophores 
such as QC1-pHLIP offer better pharmacokinetic and pharmacodynamic properties than non-targeted agents 
such as nanoparticles that partially accumulate through the enhanced permeability and retention effect (EPR).
The synthesis of the QC1-pHLIP was achieved in one step. The sulfhydryl of single cysteine residue of pHLIP 
reacts with QC1 maleimide to QC1-pHLIP in high yields (70%). It is important to note that under HPLC neutral 
buffer conditions where acetonitrile is the mobile phase, two close peaks corresponding to two interchangeable 
conformations of QC1-pHLIP were observed (Fig. 1c). Attaching a sonophore did not change the ability of pHLIP 
to protonate under acidic environments. This suggested that the binding of pHLIP was still specific as shown in 
several biological studies. Several fluorescence and PET pHLIP tracers are undergoing clinical validation58–60. 
Based on this and our data, we believe that pHLIP-based optoacoustic imaging could enter the clinic as well.
ICG-pHLIP has a higher tendency to aggregate and molecularly stack as compared to QC1-pHLIP, which 
becomes evident at higher concentrations (Fig. 2c). QC1-pHLIP, conversely, is more soluble in physiological 
conditions owing to the presence of four sulfonate groups and it shows one broad absorbance peak at 810 nm 
(Fig. 2c (right) and Fig. 2d). QC1-pHLIP yields a concentration dependent increase in optoacoustic signal in both 
phantom (Fig. 2) and in vitro studies (Fig. 3d,f). The ex vivo biodistribution studies of both ICG pHLIP and QC1 
pHLIP show tumor targeting. At the same concentration i.v. injected (120 µM), QC1 pHLIP shows a higher signal 
to noise ratio of 32-fold compared to 2-fold with ICG pHLIP. In vivo, the signal enhancement for QC1 pHLIP is 
100% and 35% for ICG pHLIP. As expected, the presence of endogenous contrast agents at greater depths in the 
presence of skin account for the dissimilarity between ex vivo and in vivo results.
Intuitively, it would be premature to assume that sonophores generally make better optoacoustic imaging 
agents than fluorophores. However, because dark quenchers efficiently absorb energy and do not emit photons, 
a higher fraction of the absorbed energy could potentially be dissipated as heat, which can make them more 
potent optoacoustic imaging agents. Our in vivo studies corroborate this hypothesis. This suggests that further 
investigations into the use of dark quenchers as sonophores are not only necessary, but could yield highly signif-
icant results. In theory, pHLIP could be conjugated to any other dark quencher. With the current trend pointing 
towards optoacoustic imaging taking on more and more complex imaging tasks, we believe that studying and 
understanding the photophysical and biological properties of small molecule sonophores will enable us to create 
new, better and more sensitive imaging probes for optoacoustic imaging. The systematic chemical studies of these 
sonophores will potentially increase the likelihood of molecular optoacoustic imaging to become a standard of 
care technology.
In conclusion, emerging concepts such as pHLIP could provide the discoveries and platforms for new and 
alternative sonophores in which we can leverage unparalleled capabilities of optoacoustic technologies for cancer 
detection in patients. Our ability to reverse engineer fluorescent ICG-pHLIP into a dark quencher QC1-pHLIP 
suggests that routine non-invasive imaging of breast cancer could be achieved with optoacoustically labeled 
pHLIP sonophore.
Materials and Methods
General. In vacuo refers to the use of a Büchi Rotavapor R-300 rotary evaporator using the vacuum pump 
V-710. All reactions were magnetically stirred, and room temperature refers to 20–25 °C. High performance 
liquid chromatography (HPLC) purification and analysis was performed on a Shimadzu UFLC system equipped 
with a DGU-20A degasser, SPD-M20A UV detector, a LC-20AB pump system, and a CBM-20A communication 
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BUS module. HPLC solvents (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in CH3CN). HPLC purifica-
tion was performed on an Atlantis dC18 reversed-phase 5 µm silica, 4.6 mm × 250 mm column. Purification was 
performed using 10–60% CH3CN method (gradient: 0–15 min 10–60%, 14 min 60%, 1 min 60-5%) at a flow 
rate of 1 mL min−1. Liquid chromatography-mass spectrometry (LC-MS) using electrospray ionization (ESI) was 
recorded using a Waters instrument with SQD detector for mass identification. A lyophilizer (FreeZone 2.5 Plus, 
Labconco, Kansas City, MO, USA) was used for freeze drying. A 100-US high pressure (New Era pump systems 
Inc., NY, USA) syringe pump was used to control the flow rate and facilitate delivery of solutions and cells inside 
the phantom flow system. An automated cell counter (Beckman Coulter, Vi-Cell viability analyzer) was used 
for counting the number of cells. Planar (2-D) fluorescence imaging was carried out using the IVIS Spectrum 
(PerkinElmer, Waltham, MA, USA). In vitro fluorescence confocal microscopy was carried out using a Leica TCS 
SP8. Fluorescence imaging was also carried out using the Odyssey Classic fluorescence scanner (Li-COR).
Chemicals. IRDye QC1 maleimide was purchased from LI-COR (Lincoln, NE, USA). Variant 3 (Var3) pHLIP 
with the amino acid sequence shown in Fig. 1b was purchased from CS Bio (Menlo Park, California, USA). Var3 
ICG-pHLIP was provided by pHLIP Inc. (Kingston, RI, USA). Intralipid® 20%, I.V. fat emulsion, Direct Red 81 
and agarose Type 1 were purchased from Sigma-Aldrich. All reagents were used without further purification.
Synthesis of QC1-pHLIP. Var3 pHLIP (2 mg, 0.65 µmol, 1.0 equiv.) was dissolved under nitrogen in DMSO/
PBS mixture (300 µL: 700 µL) followed by the addition of IRDyeQC1 maleimide (767 µg, 0.68 µmol, 1.1 equiv.). 
The reaction mixture was stirred for 24 h at room temperature. The mixture was lyophilized overnight and the 
dried powder slowly re-suspended in acetonitrile (700 µL). The mixture was purified on a HPLC. The purified 
product was lyophilized overnight to obtain 360 µg (70% yield) of a teal powder. LC-ESI-MS (ES+), m/z calculated 
for [C202H281ClN38O57S5K2]3+ 1476.60 found 1475.91 [M + 2 K + H]3+. HPLC, tR = 17.0 min (99.2% AcN), λmax 
(PBS/DMSO) 810/800 nm.
Chemical characterizations of pHLIPs. Absorption and fluorescence spectra were measured in a 
96-well plate (CorningTM CostarTM black clear bottom, Thermo Fisher Scientific) with path lengths of 0.231 cm 
and 0.300 cm for 75 µL and 100 µL, respectively. UV/Vis absorbance and fluorescence spectra were measured on 
SpectraMax® M5 Multi- Mode Microplate Reader. Samples were measured together with a corresponding refer-
ence solvent contained in a matched well and volume. Measurements were recorded in triplicates at 25 °C. The 
absorbance scan was performed with an integration time of 0.5 seconds and range from 350 nm to 1000 nm in 5 nm 
resolution. Spectra and linear calibrations were plotted using Prism 7 (GraphPad Software, La Jolla, CA, USA).
Tissue mimicking phantom preparation and experimental setup. A custom-made flow-mediated 
optoacoustic set up was prepared for optoacoustic characterizations of the agents. A clear, cylindrical hollow 
membrane tubing was placed at the center of a cylindrical mold (20 mL syringe, diameter: 2 cm, length: 14 cm). 
The soft tissue mimicking phantom was freshly prepared by adding 15% v/v intralipid® 20%, I.V. fat emulsion (to 
provide the scattering), and 0.01 mM Direct Red 81 (for absorption) to a pre-warmed solution of 5% v/v agarose 
Type 1 (solid in <37 °C) in Milli Q water (18.2 ΩM cm at 25 °C). Compared to the previously described method44, 
the amount of agarose was increased from 1.5% to 5% v/v, allowing suspension of the phantom in water and sup-
porting the weight of the hollow tubing. The mixture was poured into the mold and allowed to cool and solidify 
over a minimum of 2 hours. At each end of the tubing, a luer-lock was fitted to connect the syringe pump. The 
syringe was replaced with a 20 mL syringe filled with PBS. Air gaps were used to separate the sample and PBS. 
The flow rate was kept at 1 mL min−1 until the sample of interest reached the region of interest (ROI) for imaging. 
After imaging, the flow rate was increased 2× and the phantom was washed with at least 10 mL PBS.
Optoacoustic imaging. A pre-clinical multi-spectral optoacoustic tomography (MSOT) device (MSOT 
inVision 256, iThera Medical, Munich, Germany) was used for imaging. It is equipped with an array of 256 
detector elements which are cylindrically focused, having a central ultrasound frequency of 5 MHz and up to 
270° coverage. The phantoms were aligned so that the illumination ring coincides with the detection plane, i.e. the 
curved transducer array being centered around the phantom. Data acquisition was performed in the wavelength 
range 680–900 nm in 10 nm steps, using 10 averages frames per wavelength, which equates to 1 s acquisition 
time per wavelength per section. The optical excitation originates from a Q-switched Nd:YAG laser with a pulse 
duration of 10 ns and a repetition of 10 Hz. Light is homogenously delivered to the phantom using a fiber split 
into 10 output arms. The fiber bundle and the transducer array are stationary, and the sample holder moves along 
the z-direction allowing longitudinal acquisition of different imaging planes using a moving stage. MSOT meas-
urements were performed in a temperature controlled water bath at 34 °C. All of the variable parameters during 
the measurement were kept constant, i.e. optoacoustic gain, laser power, focus depth, frame averaging, frame rate 
and high/low pass filters. For optimal acoustic coupling, we waited at least 5 min before initiating the scan, so that 
the phantom equilibrates to the temperature of the water bath before measurement. To compare the optoacoustic 
signal of ICG-pHLIP and QC1-pHLIP, serial dilutions at 2 µM, 5 µM, 10 µM, 15 µM and 20 µM in DMSO were 
prepared. Solutions were delivered to the center of the imaging phantom device using a syringe pump. In between 
measurements, the flow device was washed with PBS (10 mL).
Optoacoustic image data processing. Spatial reconstruction and multi-spectral processing (MSP) of the 
data was performed using the ViewMSOT software suite (V3.6; iThera Medical) and a backprojection algorithm 
at 200 mm (100 µm) resolution. The normalized optoacoustic reference spectra (shown in Fig. 2e) were obtained 
from optoacoustic phantom scans. For multi-spectral unmixing, a linear regression method was used and 
excluded pixels where the number of wavelengths (>25%) fell within the negative signal. Hemoglobin (HbO2) 
and deoxyhemoglobin (Hb) reference spectra are included in the software package. Orthotopic tumors were 
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implanted in the same position and distance from the surface of the skin and from animal to animal. Hence, all 
of the animals are affected by light scattering to the same extent. In addition to the relative known location (mm) 
of the animal placed on the mice bed, the location of tumor was identified based on the presence of deoxyhemo-
globin. Quantitative information was obtained by defining the ROI manually within a 2D slice MSOT image. For 
spectrally unmixed injected pHLIPs, the mean pixel intensities per cross-section in the volume of interest (VOI) 
was first plotted as classical least square (CLS) score vs. position (mm) to assess the signal strength in the tumor. 
Decreasing signal strength over the distance away from the tumor, creating a parabolic shape is in agreement with 
the analysis. The maximum “mean signal per cross-section” was used as a quantitative indicator of probe binding 
in the tumor. Overall optoacoustic intensities (a.u.) were reported at all imaging wavelengths (680–900 nm). 
For all cases, unless otherwise stated, the (CLS) method for spectral deconvolution was used and reported as 
CLS scores. The following reference spectra were used: hemoglobin (HbO2), deoxyhemoglobin (Hb) and either 
ICG-pHLIP or QC1-pHLIP. In order to compare the direct intensities of all the images between ICG-pHLIP 
and QC1-pHLIP, the optoacoustic spectra (2 µM) were normalized to their maximum optoacoustic (810 nm) 
wavelength. The overall optoacoustic intensities (a.u., bone scale) are then overlaid with either multi-spectrally 
unmixed ICG-pHLIP (green) or QC1 (cyan) pHLIP channel.
Statistical analysis. Unpaired t-tests were performed to determine the statistical difference for in vitro 
experiments and between ex vivo non-injected and injected groups. Paired t-tests were performed to determine 
the statistical difference in vivo before and after injection. Levels of significance are as follows: ns = not significant, 
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Data is presented as mean ± SD.
In vitro fluorescence and optoacoustic imaging of ICG-pHLIP and QC1-pHLIP. A solution of cell 
free media containing saline, 20% DMSO and either ICG-pHLIP or QC1-pHLIP (10 µM) was prepared. A second 
preparation contained murine breast cancer 4T1 cells, which had been grown and maintained in Roswell Park 
Memorial Institute (RPMI) media (pH 7.4) and 10% fetal bovine serum (FBS) with penicillin/streptomycin under 
standard cell culture conditions (5% CO2 in air at 37 °C). At 70% confluence, the RPMI media was removed, 
washed with PBS, trypsinized and suspended in RPMI media. The cells were counted (1:2 dilution) and the 
appropriate volumes transferred into separate falcon tubes (0.1 × 106, 0.5 × 106, 1 × 106 and 5 × 106). The cells 
were spun down into pellets (1200 rpm for 5 min) and carefully re-suspended into the appropriate volume of 
saline. The solution containing the pHLIP imaging agents (35 µL) was added to the cell suspension (35 µL). The 
cells were mixed thoroughly by pipetting up and down. After 10 min incubation time, optoacoustic and fluores-
cent imaging was carried out.
Animal studies. All animal experiments were done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) of Memorial Sloan Kettering Cancer Center (MSKCC) 
and followed the National Institutes of Health guidelines for animal welfare. Healthy Hsd:athymic female mice 
NudeFoxn1nu (6–8 weeks old) were used in the study. The mice were split into three groups of four mice, namely 
for the ICG-pHLIP injected group, the QC1-pHLIP injected group and a non-injected control group. All animal 
procedures, other than tail vein injections, were performed with the animals under general 2% isoflurane inhala-
tion anesthesia. In order to test the ability of ICG-pHLIP and QC1-pHLIP to target tumor tissue, orthotopic allo-
grafts were created using the mouse breast cancer cell line 4T1. The 4T1 cells were injected into the 4th mammary 
fat pad just inferior to the nipple of a female mouse (1 × 106 cells in 30 µL 1:1 RPMI medium and Matrigel). The 
tumors were allowed to grow for 6–7 days (typically reaching a volume estimated from caliper measurements of 
100–150 mm3) before the ICG-pHLIP or QC1-pHLIP formulation were injected. The mice were equally split into 
groups of three cohorts (n = 4): (i) An ICG-pHLIP injected group; (ii) a QC1-pHLIP injected group; (iii) and a 
non-injected group. Tumor-bearing mice (n = 4) were imaged with the MSOT prior to injection. The experiments 
were randomized, and 200 µL of 6 mM kg−1 of ICG-pHLIP or QC1-pHLIP formulation were injected into mice 
via tail vein. The mice were re-imaged at 24 h post injection. Both pHLIP agents were dissolved in 10% v/v glucose 
in phosphate buffer saline (PBS). For MSOT imaging timepoints, the experiments were conducted on the murine 
breast cancer model (n = 3) that were injected with 200 µL of 120 µM QC1-pHLIP in PBS. Tumor optoacoustic 
signals were monitored non-invasively using the MSOT imaging system after 30 min, 4 h, 8 h, 12 h and 24 h post 
intravenous injection. Animals injected with ICG-pHLIP were imaged at 30 min, 4 h, 8 h, 12 h and 24 h on an 
IVIS Spectrum (PerkinElmer, Waltham, MA, USA) system for planar fluorescence imaging. Perfused and non 
perfused mice studies shown in Fig. S8 were a group of mice where n = 3. In general, pHLIP imaging agents were 
allowed to circulate for 24 h to study and assess the distribution and accumulation of the contrast agent using 
fluorescent and optoacoustic imaging.
Ex vivo imaging of tissue sections. After 24 h post intravenous injection and imaging, muscle and tum-
ors were harvested and fixed in 4% paraformaldehyde (PFA, MP Chemicals, Solon, OH) in PBS overnight at 
4 °C, thoroughly rinsed with PBS, then kept in 70% ethanol. Tissues were embedded in paraffin and 5 mm thick 
sections were sliced (10 µm) from the paraffin block. The sections were either imaged with confocal microscope 
(Leica TCS SP8) or stained with hematoxylin and eosin (H&E) and scanned with a Mirax digital slide scanner 
(Zeiss, Jena, Germany) for histological analysis.
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